Specialized liquid formula, effective in glycemic control. Glycemic control and prevention of diabetes complications.

1. Diamax

2. DIAMAX
• DM types 1 and 2
• Glucose intolerance
• Gestational diabetes
• Stress hyperglycemia

3. Diabetic population in the world
Diamax
• 1 adult in 10 will have
diabetes by 2030
Ranking:
• China: 92,3 mi
• Índia: 63 mi
• EUA: 24,1 mi
• Brasil: 13,4 mi
• Rússia: 12,7 mi
IDF 2012

4. Diamax
Diabetes Mellitus
Metabolic Disease
DM 1
Insuline secretion deficiency
DM 2
Insuline resistance
Diabetes:
Glycemia: ≥ 126 mg/dL
Glucose intolerance:
Glycemia: 100 to 125 mg/dL unfed

5. Intense organic catabolism with protein and fats
breach for use as energy source. Nutritional
status compromised.
Occurs hyper-insulinism status, glucagon
increase with proteolysis and lipolysis stimulus
and resulting hyperglycemia. Nutritional status
retained or overweight-obesity.
.
Diamax
Diabetes Mellitus
DM 1
Insuline secretion
deficiency
DM 2
Insuline resistance

6. SBD 2012
DM 1
Symptoms that appear quickly
• Urinating excessively.
• Extreme thirst.
• Weight loss.
• Coma
• Consciousness loss
Diamax
Early diagnosis
can save a life!
Diabetes: symptoms

7. Diabetes: symptoms
SBD 2012
DM 2
Discrete and gradual symptoms
• Urinating excessively.
• Extreme thirst.
• Increased appetite.
• Weight loss (also in obese).
• Tiredness.
• Blurred vision.
• Frequent infections (skin).
Diamax
Early diagnosis is
the best to avoid
complications!

8. Diabetes Main Complications
World Health Organ Tech Rep Ser, 916:i-viii, 1-149, 2003 e SBD 2012
Diabetic nephropathy: responsible for ~ 40% Hemodialysis
Diabetic retinopathy: blindness main cause
Circulation problems and nerve involvement.
Diamax
Acute myocardial infarction: responsible for the death of 2/3
Circulation and healing problems: increases in 40 times the
amputation risk

9. Diabetes: Control, Risk and Hospital Permanence
DIABETES
NOT COMPLICATED
OUT-PATIENT
ACTIONS
ACUTE
COMPLICATIONS
CHRONIC
COMPLICATIONS
HOSPITAL ACTIONS:
PROCEDURES AND HOSPITALIZATIONS
LOW COST
Low Risk
HIGH
PERMANENCE
High Risk
LOW
PERMANENCE
High Risk
Pimazoni. in Grupemef. 2001
Diamax

10. DIAMAX

11. Why oral feeding ?
• Preferably application
• Nutritional solution that enables the
control of glycemic homeostasis in
harmony with the daily diet
Diamax

12. BENEFITS CHARACTERISTICS
Nutritional recovery through a
specialized formula
Diamax
44%
carboidratos
39%
Lipídios
17%
proteínas
Grade A
Diten
2011
Specialized formula
Allows better glycemic
control in both short and
long term
proteins carbohydrates
lipids

13. BENEFITS CHARACTERISTICS
• Appropriate nutritional status
• Better insulin sensitivity
Diamax
Grade A/D- Diten 2011
ADA 2008/10
Nutritional Therapy:
Must avoid the excessive
energy supply
1.0
cal/ml

14. • Renal functioning protection
• Improves lipid oxidation
Diamax
• 50% Calcium caseinate
• 50% Isolated soy protein
• L-carnitine
ADA
2008/2010
Protein intake:
15 to 20% VET proteins
BENEFITS CHARACTERISTICS

15. Hermansen et al. Diabetes Care 24, 2001
Control Soy protein Soy protein x
Control
Significant difference
(%)
Initial After 6
weeks
Initial After 6
weeks
p≠ (%) p§
Total
Cholesterol
5,59±0,8
1
5,45±0,8
8
5,68±0,84 5,11±0,78 0,0041 - 8±15 0,0826
LDL 3,64±0,8
0
3,33±0,7
2
3,63±0,78 3,01±0,68 0,0044 - 10±16 0,0483
HDL 1,28±0,2
9
1,33±0,3
4
1,31±0,22 1,38±0,35 0,2024 0±20 0,8517
TG (mmol/l) 1,70±1,4
9
1,79±1,1
7
1,70±1,17 1,63±0,97 0,3632 - 22±43 0,0400
ApoB100(g/l) 0,95±0,2
6
0,98±0,2
5
1,09±0,21 0,86±0,19 0,0249 - 30±38 0,0027
Lp(a)(U/l) 32,3±37,
5
32,4±39,
8
29,5±29,9 33,9±37,7 0,3488 - 8±34 0,1769
LDL/HDL Rate 2,95±1,0
2
2,52±0,6
2
2,82±0,75 2,20±0,61 0,0007 - 12±18 0,0120
Diabetes (Soy Protein)
òBiochemical markers for
Cardiovascular Disease
Diamax

16. Diabetes (Soy Protein)
Studies suggest that
the vegetable protein
exerts protective
function to kidneys.
Diamax

17. Diabetes (Complications)
DIABETIC NEPHROPATHY
• Frequent microvascular chronic complication
Cumulative incidence in 10 years:
Brazilians 31%
Finnish 34%
Israelis 51%
• 1/3 of individuals with type 2 diabetes develop nephropathy
Diamax
Murussi et al. Arq Bras Endocrinol Metab, 47(3), 2003

18. Diabetes (L-Carnitine)
Coelho et al. Rev. Nutr., 18(5), 2005
Diamax
Hiperglicemia
Produção de
Malonil-CoA
Inibe o transporte de ácidos graxos
para obtenção de energia
Hyperglycemia
Production of
Inhibits the fatty acids transport for
energy obtainment

19. Diabetes (L-Carnitine)
Coelho et al. Rev. Nutr., 18(5), 2005
Diamax
Carnitine
Fatty acid
Metabolized for energy obtainment

20. • Slow absorption CH assists
in glycemic control
• Best palatability
Diamax
• 100% Tapioca maltodextrin
• Contains sucralose
Grade D - Diten 2011
ADA 2008/10
Carbohydrates:
33 to 50% VET
Up to 50% VET
carbohydrates
BENEFITS CHARACTERISTICS

21. Sucralose
Only sweetener agent derived from sugar through a process,
that developed an exceptionally stable molecular structure and
the body does not recognize it as sugar, is not metabolized and
is eliminated after consumption and does not have
carcinogenic effect.
Diamax
FDA
Sucralose
Maximum dose:
5mg/Kg/day

22. BENEFITS CHARACTERISTICS
• Regularization of the
intestinal transit
• Assists in glycemic control
• Fibers 15 g/L
• 65% Polydextrose
• 35% Soy polysaccharide
Diamax
Grade B - Diten 2011
Grade B - ADA
2008/10
Dietary fibers
~ 50g/day: glycemic control
14g/1000cal: DM prevention

23. POLYDEXTROSE
Jie, Z et al. Am J Clin Nutr,72:1503–9, 2000
Before and after of polydextrose consumption
Consumption days Group B (n=30)
4 g of polydextrose/day
Group C (n=30)
8 g of polydextrose/day
Group D (n=30)
12g polydextrose/day
0 101±12 95±9 88±12*
29 102±12 95±10 88±10*
*p<0,01
Diamax

24. Fecal Microbiota before and after of Polydextrose consumption
Before Group B (n=30) Group C (n=30) Group D (n=30)
Lactobacillus 0,26±0,08 0,32±0,14 0,28±0,12
Bifidobacterium 0,46±0,21 0,40±0,16** 0,52±0,19
After
Lactobacillus 1,10±0,28* 1,36±0,53* 1,92±0,48*
Bifidobacterium 1,54±0,37* 3,05±1,13* 5,29±1,74*
POLYDEXTROSE (MICROBIOTA EFFECTS)
Jie, Z et al. Am J Clin Nutr,72:1503–9, 2000
*p<0,01
**p<0,05
Prebiotic
Effect
Diamax

25. BENEFITS CHARACTERISTICS
• Cardiovascular complications
incidence reduction
39% Lip
• 54% A.T.O. Sunflower Oil
• 39% Canola Oil
• 5% Corn Oil
• 2% Soy Lecithin
Diamax
lipids

26. BENEFITS CHARACTERISTICS
• Cardiovascular complications
incidence reduction
• Insulin resistance reduction
Saturated: 5%
Monounsaturated: 26%
Poly-unsaturated: 9%
Diamax
Grade D - Diten 2011
Grade A – ADA 2008/10
AHA 2006
MUFAS: LIP preferential
SFA: up to 7% VET
SFA: up to 7% VET
lipids

27. MONOUNSATURATED FATTY ACIDS (MUFAS)
MUFAS rich diet:
Favorable effect on lipoprotein profile: #HDL $LDL
Less insulin requirement
Improves insulin sensitivity
Lower levels of:
– Postprandial and Plasmatic glycemia
– Glucagon
– Glycosuria
Diamax
lipids
Vidal et al., Rev Bras de Nutr Clin, 20(2); 2005

28. BENEFITS CHARACTERISTICS
• Homeostasis glycemic
maintenance
• Caloric density:1.0 cal/ml
• 100% Tapioca maltodextrine
• 15g/l of fibers:
65%FS - Polydextrose
• 26% MUFA (Monounsat. Fat. Ac.)
• Sweetener agent: sucralose
Diamax

29. Living well with diabetes is difficult, undoubtedly, but live with its
chronic complications is certainly much worse.
This is our challenge: setting the DIAMAX® as an ally in the quest
for improving the life quality of diabetic patients...
Diamax

30. "All data herein were collected in advertising material distributed by the companies to the market and of public domain"
INTERNAL USE ONLY
Diamax
Major Competitors
Diamax Nutri Diabetic Novasource GC GlucernaSR
Prodiet NC Support Nestlé Abbot

31. "All data herein were collected in advertising material distributed by the companies to the market and of public
domain" INTERNAL USE ONLY
Diamax
Major Competitors
Diamax Nutri Diabetic Novasource GC GlucernaSR
Prodiet NC Danone Nestle Abbot
Caloric
Density
cal/ml
1.0 1.0 1.0 1.0
Caloric
Distributio
n
PT 17% 43g/L
CH 44% 110g/L
FAT 39% 43g/L
PT 15% 39g/L
CH 39% 98g/L
FAT 46% 51g/L
PT 18% 49g/L
CH 34% 95g/L
FAT 48% 60g/L
PT 20% 47g/L
CH 47%
110g/L
FAT 33%
34g/L
CH Source
100% Tapioca
Maltodextrin
90% Maltodextrin
10% Fructose
50% Tapioca starch
34% maltodextrin
16% fructose"
50% Maltodextrin
23% Fructose
20% Maltitol
7% Fibers
Monounsat
urated
fatty acid
(%)
26 33,2 NI 25
Apresent. 200ml and 1L 200ml and 1L 200ml and 1L 220ml

32. www.prodietnutrition.com
Contact:
+55 (41) 3616 6477
export@prodietnutrition.com